William Blair analysts John Sonnier and Y Katherine Xu issued a note to investors on August 26 highlighting their best investment ideas in …
Gilead Sciences Inc (NASDAQ: GILD) issued a new warning about its hepatitis C drugs after discovering a dangerous interaction with amiodarone, a drug that …
William Blair's healthcare analyst John Sonnier came out today with a few insights on Gilead Sciences, Inc. (NASDAQ:GILD), after the company sent warnings to health providers about potentially fatal risks …
Biogen Idec Inc (NASDAQ:BIIB) shares were on the rise Friday after the company announced data from a pre-specified interim analysis of PRIME, the Phase 1b …
William Blair analyst John Sonnier is out with a research note on Gilead Sciences (NASDAQ:GILD), reiterating an Outperform rating, following the announcement from Express Scripts (NASDAQ:ESRX) …
William Blair analyst John Sonnier maintained an Outperform rating on Agenus (NASDAQ:AGEN), as its partner GlaxoSmithKline (NYSE:GSK) reported positive Phase III results with an investigational …
William Blair analyst John Sonnier reiterated an Outperform rating on Array Biopharma (NASDAQ:ARRY), following the news that the company has regained worldwide rights to binimetinib …
William Blair analyst John Sonnier maintained an Outperform rating on Halozyme Therapeutics (NASDAQ:HALO), following the company’s third-quarter results. No price target was provided.
In a research report issued today, William Blair analyst John Sonnier assigned an Outperform rating on ImmunoGen (NASDAQ:IMGN). No price target was provided.
In a research report issued today, William Blair analyst John Sonnier assigned an Outperform rating on Alexion (NASDAQ:ALXN). No price target was provided.
